Baseline data
| Arm 1 | Arm 2 | |
|---|---|---|
| Participants, N | 19 | 15 |
| Mean age, years | 51 | 56 |
| Females, n | 11 | 8 |
| Males, n | 8 | 7 |
| Complaints | ||
| Mean duration at intake, weeks | 8 | 6 |
| First episode, n | 2 | 3 |
| More than one episode, n | 4 | 2 |
| Episode every year, n | 13 | 10 |
| Mean VAS score max: pain, itch, mm | 29 | 25 |
| Mean VAS score disability, mm | 21 | 13 |
| Smoking, n | 3 | 2 |
| Comorbidity | ||
| Diabetes, n | 2 | 0 |
| Peripheral arterial disease, n | 1 | 0 |
| Raynaud’s phenomenon, n | 5 | 3 |
| Relevant medication use | ||
| Beta-blocker, n | 0 | 1 |
| Nicotine replacement drug, n | 0 | 0 |
| Acetylsalicylic acid, n | 1 | 0 |
| ACE or A2 inhibitor, n | 2 | 0 |
A2 = angiotensin. ACE = angiotensin-converting enzyme. VAS = visual analogue scale.